2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

653. Multiple Myeloma: Clinical and Epidemiological: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Pharmacology, Radiation Therapy, Women’s Health, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Bone Marrow Failure Syndromes, Hemoglobinopathies, Infectious Diseases, Viral, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

5747 Evaluating the predictive validity and clinical interchangeability of immuno-nutritional scores in multiple myeloma: A real-world analysis of ASCT, CAR-T, and bispecific therapies

Andrea Victoria Pacheco, MD, Miranda De la Luz Franco, MD2, Jay R Hydren, PhD3, Karla Mariana Castro Bórquez, MD4, Samuel Bennion5, Jennifer M Ahlstrom, BA6, Jorge Arturo Hurtado Martinez, MD, MHSc7
1 HealthTree Foundation, South Jordan, Utah, United States
2 HealthTree Foundation, South Jordan, Utah, United States
3 HealthTree Foundation, South Jordan, Utah, United States
4 HealthTree Foundation, South Jordan, Utah, United States
5 HealthTree Foundation, South Jordan, Utah, United States
6 HealthTree Foundation, South Jordan, Utah, United States
7 HealthTree Foundation, South Jordan, Utah, United States

Background: Autologous stem cell transplantation (ASCT), chimeric antigen receptor (CAR) T-cell therapy, and bispecific antibodies (BsAbs) are mainstays of multiple myeloma (MM) treatment. Baseline malnutrition and elevated systemic inflammation are well-established prognostic factors for inferior survival [1]. Therefore, incorporating objective immuno-nutritional metrics could help predict time to next treatment (TTNT) across these modalities. 

Methods: This retrospective cohort study analyzed MM patients who underwent ASCT, CAR-T, or BsAb therapy within the HealthTree Registry. A non-ASCT cohort matched via Coarsened Exact Matching (CEM) balanced age and R-ISS stage to isolate baseline differences. Kappa concordance evaluated risk-tier agreement. Eight lab-based scores: Prognostic Nutritional Index (PNI), Controlling Nutritional Status (CONUT), Geriatric Nutritional Risk Index (GNRI), modified Glasgow Prognostic Score (mGPS), neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) score, and albumin-to-globulin ratio (AGR) were calculated using laboratory values closest to diagnosis, treatment initiation and therapy discontinuation or last follow-up. To prevent collinearity, metrics were evaluated in independent multivariable Cox regressions predicting TTNT, sequentially adjusting for age, R-ISS, 1q21 abnormality, comorbidities, and induction/maintenance. Structural hypotheses (range restriction, endpoint mismatch) were evaluated to validate anticipated null associations.

Results: We evaluated 758 patients (842 episodes: ASCT=585, CAR-T=190, BsAbs=67). Median ages at treatment initiation were 61.0, 64.9, and 69.0 years, respectively. Post-therapy maintenance was utilized by 75.7% (ASCT), 10.4% (BsAbs), and 4.7% (CAR-T). CEM confirmed baseline divergence between cohorts was not an age or R-ISS artifact; matched non-ASCT patients showed significantly greater impairment (e.g., AGR Standardized Mean Difference=1.426; GNRI high-risk prevalence 28.4% vs. 10.5%). Categorical risk-tier agreement across the 8 scores was remarkably poor (e.g., PNI vs. CONUT Kappa = -0.165), suggesting non-interchangeability. 

Despite verified baseline impairments, immuno-nutritional scores universally failed to predict TTNT across cohorts.

ASCT Cohort (n=584; 268 events): Fully adjusted Cox models for all metrics yielded non-significant associations (p > 0.05; C-indices 0.472–0.535). A borderline unadjusted NLR signal (p=0.043) nullified upon clinical adjustment (p=0.986).

CAR-T Cohort (n=188; 47 events): PNI demonstrated a consistently null hazard ratio under extensive covariate adjustment (HR 0.978, p=0.33) incorporating renal impairment and 1q21 abnormality (HR 0.949, p=0.12). 

Positive Controls: Model validity was confirmed by detecting established variables (1q21 in ASCT: HR 1.941, p=0.0075; Charlson Comorbidity Index in CAR-T: HR 1.321, p=0.033). 

BsAbs Cohort (n=67): Event sparsity (4 events) precluded Cox regression; analysis remained descriptive (median PNI 43.9; CONUT 4.0).

Conclusions: The models used in this study suggest traditional laboratory-based immuno-nutritional scores (PNI, CONUT, mGPS, GNRI, NLR, LMR, HALP, AGR) may not independently predict TTNT in MM patients treated with ASCT or CAR-T, supported by the models' concurrent success in detecting known high-risk clinical drivers (1q21 and Charlson Comorbidity Index). Furthermore, variability in risk categorization between tools limits their interchangeable use in clinical practice. Regarding BsAbs, while baseline laboratory impairments exist, predictive value cannot currently be determined due to event sparsity. These findings suggest that relying solely on traditional, universal immuno-nutritional scores may be insufficient to establish an association between nutrition and MM therapy outcomes; therefore, developing MM-specific metrics that appropriately integrate systemic inflammation with clinical variables (frailty, comorbidities) and high-risk features may contribute to better understanding treatment response across patients and optimizing their overall nutritional status.

References: [1] Zhang L, Chen S, Wang W, Wang Y, Liang Y. Inflammatory and Nutritional Scoring System for Predicting Prognosis in Patients with Newly Diagnosed Multiple Myeloma. J Inflamm Res 2023;16:7. https://doi.org/10.2147/JIR.S390279.

Andrea Victoria Pacheco, MD: No relevant conflicts of interest to declare.